Share this page on LinkedIn
Share This Page on Google+
Share This Page on Twitter
tell someone about this page print this page
You are here: Contents > 2018-19 > Volume 28 Number 2 (2018-19) > MITRAL VALVE DISEASE > Mitral Valve Surgery in Patients Following MitraClip® Therapy

Mitral Valve Surgery in Patients Following MitraClip® Therapy

Shekhar Saha1,2,3, Sam Varghese1, Ahmad Fawad Jebran2, Marcus Leistner2, Heidi Niehaus2, Hassina Baraki1,2, Ingo Kutschka1,2

1Department of Cardiothoracic Surgery, University Hospital Magdeburg, Otto-von-Guericke University, Magdeburg, Germany
2Department of Thoracic and Cardiovascular Surgery, University Hospital Göttingen, Georg-August University, Göttingen, Germany
3Electronic correspondence:

Background and aim of the study: Treatment of mitral regurgitation with MitraClip® implantation is usually indicated for patients deemed high risk or inoperable. However, in several cases these patients require surgical intervention after MitraClip implantation. Herein is reported the authors’ experience of mitral valve surgery in patients who had undergone prior MitraClip implantation.

Methods: Twenty consecutive patients (median age 75 years; 25th-75th percentile 65-79 years) were identified after MitraClip implantation, and who underwent mitral valve surgery between March 2014 and July 2018. The outcomes of the patients were analyzed.

Results: The median EuroSCORE II at the time of surgical revision was 25.1% (10.4-44.7%), whereas the median Society of Thoracic Surgeons Predicted Risk of Mortality was 13.2% (7.1-20.2%). The median time to surgical revision was 130 days (8-366 days), with 25.0%


of the patients requiring surgical intervention within 24 h. The median number of MitraClips implanted was two (1-3), with 75.0% (n = 15) of patients being treated with multiple MitraClips. Indications for surgery in the MitraClip group were insufficient coaptation (n = 9), flail of the posterior mitral leaflet (PML) (n = 5), persistent atrial septal defect with left-to-right shunt (n = 3), rupture of anterior mitral leaflet (AML) (n = 2), rupture of AML and PML (n = 1), and endocarditis (n = 2). The median length of hospital stay was 22 days (14-51 days), with a median intensive care unit stay of 11 days (6-37 days). The 30-day mortality was 10.0%.

Conclusion: Surgical intervention after a MitraClip procedure may be required in case of early or late failure or infection. Redo-mitral valve surgery, even in high-risk patients, is feasible and associated with acceptable mortality rates.

The Journal of Heart Valve Disease 2018-19;28:53-58

Mitral Valve Surgery in Patients Following MitraClip® Therapy

Click the above hyperlink to view the article, right click (Ctrl click on a Mac) to open in a new browser window or tab.

Purchase this Article

Please click the button below to purchase this article. Single article purchases are provided at $50.00 per article. Upon clicking the button below, single article user account subscription details are requested and, upon successful payment, a single article user account is created. Single articles are availble in your account for seven days after purchase.